No Photo Available

Last Update

2016-12-11T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Shelley Hwang?

Dr. Shelley Hwang

Chief of Breast Surgery

Duke University

HQ Phone: (919) 660-7700

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Duke University

100 Fuqua Drive Box 90120

Durham, North Carolina 27708

United States

Company Description

Duke University Medical Center News Office is a full-service news office available 24 hours a day, every day, to respond to inquiries from the media. We are dedicated to quickly respond to media requests and encourage you to call our office if you have qu ... more

Find other employees at this company (44,684)

Background Information

Employment History

Senior Program Manager

Cisco Systems Inc

Senior Program Manager

LXE Inc.

Various

NCR Corporation

NPI Program Manager

General Electric Company

Chief, Division of Breast Surgical Oncology, Associate Professor, Department of Surgery

University of California , San Francisco

Affiliations

Member of the Breast Cancer Steering Committee
National Cancer Institute

Education

M.D.

M.D.

Duke Cancer Institute and Duke Department of Surgery

M.P.H.

Web References (60 Total References)


Speakers - NCCEO ForumNCCEO Forum

www.ncceoforum.com [cached]

Dr. Shelley Hwang

...
Dr. Shelley Hwang
Vice Chair of Research in the Department of Surgery, Chief of Breast Surgery and Professor
Duke University
...
Dr. Shelley Hwang
Vice Chair of Research in the Department of Surgery, Chief of Breast Surgery and Professor
Duke University
Dr. Shelley Hwang is Vice Chair of Research in the Department of Surgery, Chief of Breast Surgery and Professor at Duke University where she leads translational research activities in early stage and in situ breast cancer. Dr. Hwang has received local and national honors for both her clinical expertise and research, which focus on improving both cancer outcomes and quality of life in patients affected by early stage breast cancer. Her research interests include establishing the feasibility for less invasive treatments for preinvasive breast cancers, and identifying tumor- and stroma-associated determinants of cancer progression, which could be targeted for breast cancer prevention. She is the PI of COMET, a national cooperative group study in DCIS which aims to identify those patients with DCIS who may safely be managed with endocrine therapy alone. Her laboratory is focused on understanding the genomic and evolutionary basis of breast cancer progression. She also leads a team which seeks to facilitate the use of electronic data systems to improve delivery of breast cancer care. She serves as a member of the NCI Breast Cancer Steering Committee, the NCCN Breast Cancer Screening and Diagnosis Panel and Co-Chairs the Locoregional Working Group of the Translational Breast Cancer Research Consortium. Her research is supported by the NIH, DOD, PCORI, the Susan G. Komen Foundation, the Breast Cancer Research Fund, and The American Cancer Society.


Dr. Shelley Hwang, Vice ...

www.carolinabusinessconnection.com [cached]

Dr. Shelley Hwang, Vice Chair of Research, Department of Surgery and Chief of Breast Surgery and Professor, Duke University


Elite Group of Healthcare Industry Thought Leaders Converge for 2017 NC CEO Forum - PR.com

www.pr.com [cached]

· Dr. Shelley Hwang, Vice Chair of Research, Department of Surgery and Chief of Breast Surgery and Professor, Duke University


Shelley Hwang, Vice Chair of ...

www.ncceoforum.com [cached]

Shelley Hwang, Vice Chair of Research, Department of Surgery and Chief of Breast Surgery and Professor, Duke University


NC Research News | North Carolina Health News

www.northcarolinahealthnews.org [cached]

Surgeon Shelley Hwang (right) with one of her patients. Photo courtesy: Twitter/ @DukeCancer

The setting for those remarks was an annual breakfast presented Nov. 10 in Durham by the American Cancer Society's Cancer Action Network with the goal of celebrating achievement and raising awareness and funding for research in the field. Representatives of North Carolina's three National Cancer Institute-designated comprehensive cancer centers updated brought on recent progress, each citing a team-based approach.
Shelley Hwang, a surgeon at the Duke Cancer Institute, spoke about her role as a principal co-investigator in a $13.4 million study of low-risk ductal carcinoma in situ, or DCIS. The condition, affecting 60,000 American women annually, involves cancerous cells contained in the ducts of the breast, that have not yet spread, Hwang said.
"We treat it very much like we do cancer, and it has very much the same treatment side effects," she said. "It really hasn't brought about the reduction in breast cancer we would like to see."
Hwang: Some patients treated too aggressively
Based on cooperation among different medical and scientific disciplines, Hwang said, clinicians have been asking questions about when treatment for such conditions is warranted and when an aggressive approach might outweigh benefits.
"Why are these people continuously radiated and treated … and potentially have both breasts removed? she asked. "The alternative to this would be close monitoring, with treatment only if the patient develops cancer."
Hwang said if a woman is 60 years old and diagnosed with DCIS, "You are much more likely to die of non-breast cancer related causes."
The U.S. health care system currently spends $250 million annually treating DCIS, in many cases without strong evidence to justify the treatment, said Hwang, who was recognized along with Dr. Laura Esserman, of the University of California, San Francisco, as one of Time magazine's 100 most influential people of 2016.
...
"... I'm happy to see doctors like Laura Esserman and Shelley Hwang, who are at the top of their field, saying, 'Whoa, let's put a brake on all these radical surgeries,' Etheridge said in the magazine.
...
Hwang also touched on trials involving PVS-RIPO, a genetically engineered poliovirus that is being investigated as a new anti-cancer agent at Duke.

Similar Profiles

Other People with this Name

Other people with the name Hwang

George Hwang
aJile Systems Inc

Marguerite Hwang
Apex Maritime Co. Inc

Tony Hwang
Monsieur Touton Selection Ltd

Melina Hwang
Asia Online Publishing Group Sdn. Bhd.

Richard Hwang
Cushman & Wakefield Inc

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory